GIM
SAGE

Granahan Investment Management’s Sage Therapeutics SAGE Stock Holding History

Granahan Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-347,529
Closed -$3.77M – 198
2024
Q2 		$3.77M Buy
347,529
+191,158
+122% +$2.45M 0.15% 141
2024
Q1 		$2.93M Buy
+156,371
New +$3.61M 0.1% 149
2016
Q4 		– Sell
-316,065
Closed -$14.6M – 242
2016
Q3 		$14.6M Sell
316,065
-163,210
-34% -$6.64M 0.48% 90
2016
Q2 		$14.4M Sell
479,275
-7,710
-2% -$257K 0.53% 76
2016
Q1 		$15.6M Buy
486,985
+212,100
+77% +$7.47M 0.57% 63
2015
Q4 		$16M Sell
274,885
-36,380
-12% -$1.8M 0.55% 66
2015
Q3 		$13.2M Buy
311,265
+36,600
+13% +$2.26M 0.41% 88
2015
Q2 		$20.1M Buy
274,665
+125,509
+84% +$8.07M 0.57% 64
2015
Q1 		$7.49M Buy
+149,156
New +$6.41M 0.21% 151

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Granahan Investment Management's SAGE Position: Q3 2024 in Review

Granahan Investment Management sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 347,529 shares — an estimated $3.77M sold.

Granahan Investment Management first reported a position in SAGE in Q1 2015 and held it in 9 quarters. The position peaked at $20.1M in Q2 2015. 175 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • Granahan Investment Management reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Granahan Investment Management sold 347,529 Sage Therapeutics shares in Q3 2024, an estimated $3.77M.
  • Granahan Investment Management first reported a position in Sage Therapeutics in Q1 2015 and held it in 9 quarters.
  • Granahan Investment Management's Sage Therapeutics position peaked at $20.1M in Q2 2015.
  • 175 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Granahan Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.